GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD) dementia.

Key facts

Study ID
NCT03823404
Run by
Cortexyme Inc.
People needed
643
Starts
2019-03-28
Expected to finish
2022-01-01
Last updated by the study team
2023-02-23

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.